/

Società

Lu

Non verificato

Lutris Pharma

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaFinanzaSanità

6 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

07/07/2025

Salute

Fitness

Fiere

Eventi

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025

Fonte

Emittente

1.00

0

29/04/2025

Farmaceutica

Sanità

Economia

Management

Organizzazione Aziendale

Biologia

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Fonte

Emittente

1.00

0

28/04/2025

Farmaceutica

Sanità

Biologia

Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel Demonstrating Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at AACR Annual Meeting 2025

Fonte

Emittente

1.00

0

26/03/2025

Farmaceutica

Sanità

Finanza

Biologia

Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025

Fonte

Emittente

1.00

0

Press Release cover image

28/01/2025

Farmaceutica

Sanità

Finanza

Banca

Mutui

Risparmio/Affari personali

Leasing

Gestione dei titoli obbligazionari

Fondi di investimento

Euro-obbligazioni

Biologia

Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness

Fonte

Emittente

1.00

0

Press Release cover image

15/10/2024

Farmaceutica

Sanità

Biologia

Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment of EGFRI-Induced Acneiform Rash in Patients with Metastatic Colorectal Cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0